FDLI Publishes Article on The Value of FDA Pre-Submission Meetings & Enhancements under PDUFA VI Authored by EAS Regulatory Intern

The prestigious FDLI Update November/December 2017 Student Corner included an article written by EAS Regulatory Intern and recent Georgetown University graduate, Rahul. The article, The Value of FDA Pre-Submission Meetings & Enhancements under PDUFA VI, discusses how pharma companies can manage risks through proper communication with FDA throughout the drug development process.

Posted in 2018 January, EAS in Action.